今日（7月18日），化工板块开盘后持续上攻，反映化工板块整体走势的化工ETF（516020）震荡拉 升，盘中场内价格最高涨幅达到1.63%。 成份股方面，截至发稿，聚氨酯龙头万华化学飙涨7%，华峰化学大涨超4%，新凤鸣、华鲁恒升、圣泉 集团等涨超3%，盐湖股份、藏格矿业、扬农化工等多股涨超2%。 | | | 分制 多日 1分 5分 15分 30分 60分 日 周 月 更多 | | | | | | F9 盘前盘玩 盘加 九粒 测试 工具 @ 0 > | | RIETF O | | 516020 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 0.62 | | | | | 516020(K.I.ETF) 10:24 价 0.624 图数 0.000(1.46%) 100 0.622 版交量 0 IOPV 0.6247 | | | 2025/07/18 | | 0.624 | | +0,009 +1,469 | | 0.620 | | 620 NASUN | | | | | | | 0.8596 ...

Group 1 - The Nasdaq China Golden Dragon Index rose by 1.23%, indicating a positive performance for Chinese assets overnight [1] - Hong Kong stocks continued to rise, with the Hang Seng Index and Hang Seng Tech Index both opening over 1% higher, led by tech giants such as Kuaishou and Bilibili, which rose over 3% [1] - The Hong Kong Internet ETF (513770) saw an increase of 1.7%, reflecting strong investor interest in internet stocks [1] Group 2 - Tianfeng Securities noted that Hong Kong stocks are currently at historical low valuations, with a rebound in foreign investment interest expected due to easing global liquidity and domestic growth policies [2] - Galaxy Securities projected an upward trend for the Hong Kong market, emphasizing the structural nature of the rally and the high investment opportunities in the tech sector [2] - The Hong Kong Internet ETF (513770) has attracted a total net inflow of 1.042 billion yuan over the past 10 trading days, indicating strong capital inflow into the sector [2] Group 3 - The Hong Kong Internet ETF (513770) and its linked funds heavily invest in the "ATM" trio (Alibaba, Tencent, Xiaomi), with a combined weight of 61.06%, making it a key tool for AI investments in Hong Kong [4] - Since the start of the current market rally until the end of June, the CSI Hong Kong Internet Index has seen a cumulative increase of over 28%, outperforming both the Hang Seng Index and the Hang Seng Tech Index [4] - The average daily trading volume of the Hong Kong Internet ETF (513770) for the year is 594 million yuan, highlighting its liquidity and appeal for investors [5] Group 4 - The CSI Hong Kong Internet Index has shown significant annual performance fluctuations, with a peak increase of 109.31% in 2020 and a decline of 36.61% in 2021, indicating volatility in the sector [6] - The index's performance over the past five years reflects a mixed trend, with a notable recovery of 23.04% in 2024, suggesting potential for future growth [6]

Core Viewpoint - The photovoltaic (PV) sector has experienced significant competition and adjustment, leading to a decline in the financial performance of many companies within the industry, despite previous growth driven by policies and global energy transition demands [1][2][3]. Industry Overview - The PV industry in China has evolved from relying on foreign technology to achieving self-innovation and leading high-end manufacturing, establishing a competitive edge globally [2][3]. - China has been the world's largest PV producer since 2007, with over 80% of global production capacity and 55% of new installations in 2024 [3][4]. Supply and Demand Dynamics - The rapid expansion of production capacity has led to a significant oversupply in the PV industry, with capacities for silicon wafers, batteries, and modules reaching 753GW, 654GW, and 588GW respectively in 2024, far exceeding actual demand [4]. - Demand growth for new installations has slowed, with the EU and the US experiencing a decline in growth rates, leading to concerns about future demand [5][7][8]. Price Trends and Financial Impact - The oversupply has resulted in a drastic drop in prices for key materials, such as polysilicon, which saw a nearly 90% decrease from its peak [10]. - The financial performance of PV companies has deteriorated, with a projected revenue decline of 18.34% and a shift from a profit of 122.1 billion yuan in 2023 to a loss of 20.59 billion yuan in 2024 [14]. Policy Response and Future Outlook - Recent "anti-involution" policies aim to address the chaotic competition in the PV sector, promoting quality improvement and the orderly exit of outdated capacities [15][16]. - The introduction of these policies has already shown positive effects, with polysilicon prices increasing by 39% in a short period, indicating potential recovery in the industry [15]. - The PV sector is expected to undergo consolidation and enter a stable development phase, with long-term growth prospects supported by ongoing global clean energy demand and technological advancements [16][17]. Investment Opportunities - The current valuation of the PV sector, with a price-to-book ratio of 1.90, suggests that potential risks have been somewhat mitigated, presenting investment opportunities as the market stabilizes [18]. - The Huatai-PineBridge fund's PV ETF is highlighted as a convenient option for investors looking to capitalize on the sector's recovery [19].

7月17日，港股创新药全天领涨，势如破竹，高纯度+高弹性标的港股通创新药ETF（520880）场内价格 一度涨近6%，收涨5.23%，全天成交额3.74亿元，环比放量超两倍，创历史天量！ 截至今日，港股通创新药ETF（520880）已连涨7日，标的指数区间累计上涨9.4%。 | | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | | | 2157 | 乐普生物-B | | 6.370 | 1.260 | 24.66% | | 2 | 2162 | 康诺亚-B | | 57.250 | 7.250 | 14.50% | | 3 | 9926 | 康方生物 | | 139.500 | 13.500 | 10.71% | | 4 | 6160 | 百济神州 | | 183.300 | 17.600 | 10.62% | | 5 | 2096 | 先声药业 | | 11.940 | 1.040 | 9.54% | | 6 | 1530 | 三生制药 | | 30.600 | 2.650 | 9.48% | | 7 ...

周四（7月17日），算力硬件股继续走强，光模块龙头冲锋，高光模块含量的创业板人工智能盘中再度 刷新高。成份股大面积飘红，其中大牛股新易盛涨超8%叒创新高，最新市值超1800亿元，单日成交额 达120亿元居A股榜首！此外，联特科技、太辰光均涨超5%，光库科技、中际旭创、天孚通信涨幅也均 在2.5%以上。 热门ETF方面，同标的指数规模最大、流动性突出的创业板人工智能ETF（159363）全天强势，场内收 涨3.12%收盘价创新高，单日成交额达4.11亿元为历史次高。 业绩端，近期算力硬件板块内部多个代表性公司发布二季度经营情况，表现普遍超预期，利润情况更 优。核心原因是海外AI需求旺盛，产业核心玩家受益于此趋势。二季度经营情况公布后，市场预计明 后年板块将高速增长，板块内公司的利润、收入及利润率有望超预期，因此对相关公司2025年全年及 2026年经营情况进行上修。 估值端，国盛证券认为，A股算力产业链是稀缺的真成长板块。未来随着AI商业化的持续落地，算力产 业趋势有望成为上一轮云计算的黄金十年的强化版，A股AI主线中的优秀企业估值体系有望向成长股切 换。海外算力复苏趋势已经较为显著，坚定推荐算力产业链相关企业 ...

Group 1 - The Color Metal Leader ETF (159876) experienced a price increase of 0.66% after three consecutive days of decline, with a net subscription of 600,000 units, totaling 2.53 million yuan in the last two days [1] - Since the low point on April 8, the ETF has risen by 20.84%, outperforming the Shanghai Composite Index (13.57%) and the CSI 300 Index (12.40%) [1] - Lithium stocks led the gains, with Tianqi Lithium and Ganfeng Lithium both rising over 3%, and Shengxin Lithium Energy increasing by more than 2% [1] Group 2 - Tianqi Lithium is expected to turn a profit in its mid-year report, with a net profit forecast between 0 to 155 million yuan, a significant recovery from a loss of 5.206 billion yuan in the same period last year [2] - Ganfeng Lithium's losses are expected to narrow, with a forecasted net loss of 300 million to 550 million yuan, compared to a loss of 760 million yuan last year [2] - The lithium sector is seeing accelerated resource clearance, with domestic battery production increasing by nearly 40% year-on-year, benefiting the lithium price and the industry's long-term profitability [2][3] Group 3 - Among the 60 companies covered by the Color Metal Leader ETF, 27 have disclosed mid-year performance forecasts, with over 80% expecting profits, and 10 companies predicting a doubling of net profits [3] - Northern Rare Earth is expected to see a net profit increase of 1882% to 2014% year-on-year, leading the sector [3] - The overall improvement in the non-ferrous metal industry is attributed to multiple factors, including macro policy benefits, geopolitical disturbances, and emerging demand from sectors like new energy vehicles and robotics [3][5] Group 4 - As of the end of June, the market-to-book ratio of the CSI Nonferrous Metals Index was 2.24, indicating a relatively low valuation compared to its historical median of 2.52, suggesting a high cost-performance ratio for investment [6] - The Color Metal Leader ETF and its linked funds track the CSI Nonferrous Metals Index, which has significant weightings in copper (26.1%), gold (16.3%), aluminum (15.8%), rare earths (8.5%), and lithium (7.7%), providing risk diversification [7]

Market Overview - The market experienced a strong upward trend throughout the day, with the ChiNext Index leading the gains. The total trading volume in the Shanghai and Shenzhen markets reached 1.54 trillion yuan, an increase of 97.3 billion yuan compared to the previous trading day. By the end of the trading session, the Shanghai Composite Index rose by 0.37%, the Shenzhen Component Index increased by 1.43%, and the ChiNext Index gained 1.76% [1] Innovation Drug Sector - The innovative drug sector led the market gains today, with the Innovative Drug ETF (517110) opening strong and ultimately closing up by 4.40% [2] - Recent positive news for the innovative drug sector includes the inclusion of the domestically developed antiviral drug Qiruisuo Wei in the World Health Organization's priority list for children's medicines, which could provide accessible and affordable treatment for children globally [4] - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, including 16 specific initiatives aimed at enhancing research support, integrating innovative drugs into insurance directories, and improving clinical application [5] Performance Reports - The CXO sector has shown a positive performance trend, with companies like WuXi AppTec and Boteng Co. forecasting significant revenue growth. WuXi AppTec expects to achieve revenue of 20.799 billion yuan in the first half of 2025, a year-on-year increase of 20.64%, with adjusted net profit projected to rise by 44.43% [6] - The trend of innovation in the drug sector is expected to continue, with a focus on "innovation + internationalization" as a core direction for the pharmaceutical industry. The recovery of overseas business orders and performance in the CXO sector is also noted [6] Internationalization of Innovative Drugs - China's share of global innovative drug business development (BD) transactions has increased significantly, from 3% in 2019 to 13% in 2024, with the monetary share rising from 1% to 28%. The total amount for license-out transactions in the first half of 2025 is approaching 66 billion USD [6][7] - 2025 is anticipated to be a breakout year for Chinese innovative drugs in overseas markets, with numerous products expected to exceed transaction values of 3-5 billion USD [7] Investment Opportunities - The ongoing issuance of the Sci-Tech Innovation Drug ETF (subscription code: 589723) is gaining traction, tracking the Shanghai Stock Exchange Sci-Tech Innovation Drug Index, which focuses on leading companies in the innovative drug sector [7] - The communication ETF and ChiNext AI ETF also showed positive performance, closing up by 3.89% and 3.04% respectively [7]

Core Viewpoint - The Chinese innovative drug market is experiencing significant growth, driven by policy support, increased capital investment, and industry maturation, leading to a sustained release of innovative drug value [1][4][7] Group 1: Policy Support - Since 2015, a series of medical reform policies have been implemented, facilitating a profound transition from generic to innovative drugs in China [3] - In 2025, several supportive policies for innovative drugs were introduced, including optimization of clinical trial reviews and adjustments to insurance drug lists [3][4] - The establishment of a comprehensive support system for innovative drug development has been noted, aiding China's transformation into a strong player in the innovative drug sector [4] Group 2: Capital Investment - The financing environment for innovative drugs is improving, with significant increases in BD (business development) transactions and IPOs in the Hong Kong market [4][6] - In the first five months of 2025, BD transaction amounts reached $598 million, surpassing the total for 2024 [4] - The reintroduction of the fifth set of listing standards on the Sci-Tech Innovation Board is expected to stimulate investment in innovative drug companies [6] Group 3: Industry Development - The number of approved innovative drugs in China has significantly increased, with 48 new approvals in 2024, five times that of 2018 [6] - China has become a major player in the global innovative drug field, with a substantial pipeline of research and development [7] - The combination of strong national support and the maturation of innovative drug companies indicates that the industry is entering a phase of substantial returns [7]

Wind数据显示，截至7月17日，全市场共有197位基金经理离任，涉及104家公募机构，离任人数较去年 同期增加18位；同期新聘基金经理308位，较去年同期减少13位。尽管人员更替总量上升，基金经理总 数仍较年初增加111位至4056人，折射出行业在人才流动中持续扩容的态势。 而华夏基金与中欧基金以新聘11人并列行业首位，南方、招商各增10人，兴证全球基金新聘9人，富国 基金、工银瑞信基金、易方达基金、中金基金、银华基金均新聘8位，加速填补空缺。 值得注意的是，共有34家基金公司年内暂无基金经理离职或新聘变动，其中包括前海开源基金、银河基 金、海富通基金、国联安基金、东方基金等公司，凸显部分中小机构的团队韧性。 具体来看，嘉实基金以13位基金经理离任高居行业榜首，远超其去年全年的6位，创下历史峰值。 | 序号 | 基金公司 | 离任基金经理数 | 新聘基金经理数 | 基金经理数 | 基金经理变动率(%) | | --- | --- | --- | --- | --- | --- | | 1 | 眾求重等 | 13 | 5 | 104 | 11.61 | | 2 | 作夏ま金 | 5 | 11 | 131 | ...

Group 1 - The core viewpoint of the articles emphasizes that the innovative drug sector in China is experiencing a transformation driven by international recognition, policy support, and market dynamics, leading to a potential revaluation cycle [1][5][9] - The total value of license-out transactions for Chinese innovative drugs exceeded $50 billion in 2023, with multiple drugs receiving FDA approval, indicating growing global market acceptance [1][5] - The Hong Kong stock market has become a preferred listing venue for Chinese innovative drug companies due to its international financing environment and flexible listing regulations, hosting numerous leading firms in cutting-edge fields such as oncology and gene therapy [1][5] Group 2 - The newly launched Hong Kong Stock Connect Innovative Drug ETF by Harvest Fund aims to provide investors with a one-click solution to invest in core assets of innovative drugs, tracking the CSI Hong Kong Stock Connect Innovative Drug Index [2][9] - The CSI Hong Kong Stock Connect Innovative Drug Index includes 50 companies involved in innovative drug research and development, with the top ten companies accounting for over 60% of the index's weight, showcasing significant representativeness [2][3] - As of July 15, 2025, the index has shown impressive performance, with a one-year increase of 109.13% and a year-to-date increase of 66.23%, outperforming similar indices and the broader market [4][5] Group 3 - The A-share Sci-Tech Innovation Board complements the Hong Kong market by attracting innovative drug companies with independent intellectual property, providing a financing channel for high-growth biotech firms [6][9] - The newly established Sci-Tech Medicine ETF by Harvest Fund tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index, covering various segments including innovative drugs and vaccines [6][9] - The combination of the Hong Kong and A-share markets creates a comprehensive investment strategy for Chinese innovative drugs, allowing investors to capture opportunities across the entire industry chain [9][10] Group 4 - The dual-market strategy of investing in both Hong Kong and A-share markets allows for a diversified approach, with the Hong Kong ETF focusing on mature innovative drug companies and the A-share ETF targeting early-stage firms with high growth potential [10][11] - This strategy aims to mitigate risks associated with market volatility while maximizing long-term investment value in the innovative drug sector [10][11] - Harvest Fund has developed a comprehensive ETF product line in the biopharmaceutical sector, including various thematic products to capture key industry opportunities [11]